Clinical trials · California
Macular Degeneration clinical trials in California
We’re tracking 43 recruiting macular degeneration studies with a site in California — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT06662162Recruiting
Microcurrent therapy for dry age-related macular degeneration
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
Poway, CaliforniaAges 60 years+ - NCT07440225RecruitingPhase 2/Phase 3
Testing a new drug for wet macular degeneration
This trial tests a new medicine called EYE201/MK-8748 for people who have wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). It's for those who haven't had treatment before and were diagnosed recently.
Glendale, CaliforniaAges 50 years+ - NCT07496567RecruitingPhase 2/Phase 3
Study of EYE201 for wet age-related macular degeneration
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
Encino, CaliforniaAges 50 years+ - NCT03999801Enrolling by invitationPhase 2
Long-term follow-up for a subretinal eye treatment
This study checks how well a previous eye treatment (RGX-314) lasts over time. There is also an extra “other eye” study for people with age-related macular degeneration affecting both eyes.
Santa Barbara, CaliforniaAges 50 years+ - NCT06237127Recruiting
Goji berries vs. fiber for age-related macular degeneration
This study compares the effects of eating goji berries versus taking fiber wafers on age-related macular degeneration (AMD). It looks at whether goji berries or fiber can help slow down the eye condition, especially for people with a family history of AMD.
Sacramento, CaliforniaAges 65–95 - NCT03178149RecruitingPhase 1
Study of a new eye treatment for dry macular degeneration
This Phase 1 trial tests the safety and side effects of ASP7317 in older adults whose central vision is worsening from dry age-related macular degeneration (geographic atrophy). If you qualify, you would receive treatment in the study eye and be closely monitored for about a year.
Los Angeles, CaliforniaAges 50 years+ - NCT06087458RecruitingPhase 1/Phase 2
Study of VOY-101 for advanced dry age-related macular degeneration
This trial is testing a new treatment called VOY-101 for people with advanced dry age-related macular degeneration (geographic atrophy). It aims to see if the drug can slow or stop vision loss in this condition.
Poway, CaliforniaAges 60 years+ - NCT06635148RecruitingPhase 2
Long-term study for geographic atrophy treatment
This study is for people who already took part in a previous trial for geographic atrophy (a late stage of dry age-related macular degeneration) and received the study drug or a sham. It looks at the long-term safety of the treatment over time.
La Jolla, CaliforniaAges 60 years+ - NCT07064759RecruitingPhase 3
Gene therapy injection for wet age-related macular degeneration
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
San Francisco, CaliforniaAges 50 years+ - NCT07614776RecruitingPhase 3
New Eye Injection Treatment for Age-Related Macular Degeneration
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
Fullerton, CaliforniaAges 50 years+ - NCT07630649RecruitingPhase 2
Gene therapy for wet age-related macular degeneration in second eye
This study tests a one-time gene therapy injection (ixoberogene soroparvovec) in the second eye of people with wet age-related macular degeneration who have already responded well to anti-VEGF injections. The goal is to see if this gene therapy can help preserve or improve vision in that eye.
Bakersfield, CaliforniaAges 50 years+ - NCT07007065RecruitingPhase 3
Study of a gene therapy for wet age-related macular degeneration
This trial tests a one-time gene therapy injection for wet AMD that may reduce the need for regular eye injections. It is for people who have already responded to anti-VEGF injections but want a longer-lasting treatment.
Campbell, CaliforniaAges 50 years+ - NCT04627428RecruitingPhase 1/Phase 2
Stem-cell–made eye tissue transplant for dry macular degeneration
This early-stage study tests whether a stem-cell–derived transplant to the back of the eye is safe and tolerable in people with dry age-related macular degeneration (AMD). If you qualify, you may receive the transplant and have close follow-up to watch for side effects.
Beverly Hills, CaliforniaAges 55 years+ - NCT07482176RecruitingPhase 3
Gene therapy trial for wet age-related macular degeneration
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
Bakersfield, CaliforniaAges 50 years+ - NCT05197270RecruitingPhase 1/Phase 2
Study drug 4D-150 for wet macular degeneration not responding enough
This early-stage study tests 4D-150 (a one-time injection into the eye) for “wet” age-related macular degeneration to see if it can better control leaking blood vessel growth and reduce fluid. It’s for people who are already getting anti-VEGF injections but still need ongoing treatment because of signs of fluid on special eye scans.
Oxnard, CaliforniaAges 50 years+ - NCT07587515RecruitingPhase 1/Phase 2
New Eye Drop Treatment for Wet Age-Related Macular Degeneration
This study tests a new experimental eye drop (EYC-0305) for wet AMD, a common cause of vision loss in older adults. The goal is to see if it can slow or prevent further damage to central vision.
Beverly Hills, CaliforniaAges 50 years+ - NCT07441642RecruitingPhase 2
Testing FWY003 eye drops for geographic atrophy (dry AMD)
This trial tests a new eye drop called FWY003 against a placebo (an inactive drop) to see if it can slow the progression of geographic atrophy (the dry form of age-related macular degeneration). It may help people who have moderate vision loss from this condition.
Huntington Beach, CaliforniaAges 50 years+ - NCT05481827Enrolling by invitationPhase 2
Safety follow-up for GT005 in geographic eye damage
This study checks the long-term safety of GT005, a treatment you received in an earlier study, for geographic atrophy related to age-related macular degeneration. It mainly asks you to come to follow-up visits and confirm how you are doing over time.
Poway, CaliforniaAges 55 years+ - NCT04853251RecruitingPhase 4
Study of corneal cells after a ranibizumab eye implant
This trial checks how well corneal endothelial cells (cells that help keep the cornea clear) do in people with neovascular age-related macular degeneration (nAMD) who are treated with a port-delivery implant that releases ranibizumab. It also helps doctors understand whether this method changes corneal health and stays safe while controlling the eye disease.
Sacramento, CaliforniaAges 50 years+ - NCT07516132RecruitingPhase 3
Long-term safety study of axitinib implant for wet macular degeneration
This study follows people who completed an earlier 2-year trial of OTX-TKI, a small implant placed in the eye to treat wet age-related macular degeneration (a condition causing vision loss). Researchers want to make sure the treatment remains safe over time.
Bakersfield, CaliforniaAges 50 years+ - NCT07680244Recruiting
Testing a new tool to see retina in eye scans
This trial is testing a new software tool that helps doctors see and assess different parts of the retina in eye scans. It aims to see how well the tool works in people with and without certain retina conditions.
Mountain View, CaliforniaAges 18 years+ - NCT02402660Enrolling by invitationPhase 2
Test ALK-001 for Stargardt disease eye changes and comfort
This Phase 2 study tests how well ALK-001 is tolerated and whether it can slow or improve vision-related changes in people with Stargardt disease. It mainly looks at safety (tolerability) and signs in the eye over about 24 months.
Los Angeles, CaliforniaAges 8–70 - NCT06375239Recruiting
Study of tests for tracking vision in retinal disease
This study will check if certain vision tests work well in people with retinal diseases like retinitis pigmentosa or Stargardt. Results will help design future trials.
Irvine, CaliforniaAges 18 years+ - NCT07205887RecruitingPhase 2
Study of EYE103 for wet AMD or macular edema after BRVO
This trial tests an investigational drug called EYE103 injected into the eye to treat two conditions: wet age-related macular degeneration (AMD) or macular edema following a branch retinal vein occlusion (BRVO). It looks at how safe and effective the drug is for people who have not had treatment before or have not responded well to previous treatments.
Glendale, CaliforniaAges 18 years+
Macular Degeneration trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting macular degeneration studies listed above.
- Retinal Consultants Medical Group · 8 studies
- California Retina Consultants · 7 studies
- Retina Consultants of San Diego · 5 studies
- Northern California Retina Vitreous Associates Medical Group · 4 studies
- Orange County Retina Medical Group · 3 studies
- Retina Consultants of Orange County · 3 studies
- Adverum Clinical Site 109 · 2 studies
- Adverum Clinical Site 169 · 2 studies
What taking part in a macular degeneration study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Macular Degeneration trials in other states
Common questions
- Are there macular degeneration clinical trials in California?
- Yes. We're currently tracking 43 recruiting macular degeneration studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a macular degeneration study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a macular degeneration trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New macular degeneration studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.